Patents by Inventor John Desjarlais

John Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20210102003
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20210101965
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 8, 2021
    Inventors: Peter C. BACIU, Yanbin LIANG, Jason GUU, Matthew BERNETT, Umesh MUCHHAL, John DESJARLAIS
  • HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
    Publication number: 20210102002
    Abstract: Novel Heterodimeric IgG-Like Bispecific Antibodies (HILBAs) are provided herein. Such bispecific antibodies are similar to IgG in structure and, thus, do not exhibit a limited half-life like previous antibody fragment-based bispecifics. Moreover, such heterodimeric IgG-like bispecific antibodies advantageously do not entail complicated generation methods such as Fab arm exchange and common light chain methods. Unlike canonical IgG antibodies, the HILBAs described herein include at least one monomer that is from N- to C-terminus: a VH-scFv linker-VL-CL-domain linker-CH1-hinge-CH2-CH3.
    Type: Application
    Filed: August 6, 2020
    Publication date: April 8, 2021
    Inventors: Matthew Bernett, John Desjarlais, Eric Chang
  • Optimized anti-CD3 variable regions
    Patent number: 10968276
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 6, 2021
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
    Publication number: 20210095030
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Application
    Filed: March 16, 2020
    Publication date: April 1, 2021
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • IL-7-FC-FUSION PROTEINS
    Publication number: 20210070824
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Application
    Filed: May 15, 2020
    Publication date: March 11, 2021
    Inventors: Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10889653
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 12, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Bispecific antibodies that bind to CD38 and CD3
    Patent number: 10858451
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Y. Chu, Gregory Moore, John Desjarlais
  • Heterodimeric proteins
    Patent number: 10858417
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Heterodimeric human IgG1 polypeptides with isoelectric point modifications
    Patent number: 10851178
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: December 1, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
  • MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS
    Publication number: 20200339624
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Application
    Filed: December 19, 2019
    Publication date: October 29, 2020
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachichi, John Desjarlais
  • Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
    Patent number: 10793632
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 6, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Bispecific checkpoint inhibitor antibodies
    Patent number: 10787518
    Abstract: The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: September 29, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
  • Complement component C5 antibodies
    Patent number: 10752678
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 25, 2020
    Assignees: ALLERGAN, INC., XENCOR, INC.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • Heterodimeric proteins
    Patent number: 10738133
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND PSMA
    Publication number: 20200216559
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 9, 2020
    Inventors: Gregory Moore, John Desjarlais, Seung Chu
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20200199251
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: October 22, 2019
    Publication date: June 25, 2020
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20200165356
    Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
    Type: Application
    Filed: April 4, 2019
    Publication date: May 28, 2020
    Inventors: John Desjarlais, Alex Nisthal, Seung Chu
  • BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
    Publication number: 20200123259
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon